Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality

Giancarlo Castaman, MD1  Augusto B. Federici, MD2

1 Center for Bleeding Disorders, Department of Heart and Vessels, Careggi University Hospital, Firenze, Italy
2 Department of Oncology and Hematology, University of Milan, Hematology and Transfusion Medicine, L. Sacco University Hospital, Milan, Italy


Abstract

Type 2B von Willebrand disease (VWD2B) is a rare, autosomal-dominant inherited bleeding disorder, characterized by an enhanced ristocetin-induced platelet aggregation in platelet-rich plasma and often with variable degree of thrombocytopenia and loss of high-molecular-weight multimers of von Willebrand factor (VWF). All these phenomena are caused by a mutant VWF, normally synthesized and assembled by endothelial cells, but with heightened affinity binding to the platelet receptor glycoprotein Ib-α (GpIb-α). When this abnormal VWF is released into the circulation and under specific clinical circumstances, in vivo platelet clumping is observed. Mutations, invariably clustered in exon 28 of the VWF gene encoding for the VWF A1 domain involved in VWF binding to GpIb-α, are responsible for VWD2B phenotype. Clinical and laboratory phenotype appears strongly related to the type of VWF-causative mutations. However, recent evidences suggest that a true platelet defect is also present in this type, with several morphological and functional abnormalities being detected in a subset of VWD2B patients.

Keywords
- von Willebrand disease
- type 2B
- thrombocytopenia
- inherited bleeding disorders
- platelets
- platelet function disorders

von Willebrand disease (VWD) is a common autosomal-dominant inherited bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor (VWF), a multi-adhesive protein which binds platelets to exposed subendothelium, participates in platelet aggregation and carries factor VIII in circulation. VWD is classified into six different types (►Table 1). Type 1 and 3 VWD reflect the partial or complete quantitative deficiency of VWF, respectively, while four type 2 variant reflect different qualitative defects of VWF.1 Type 2 displays a wide heterogeneity of functional abnormalities reflecting the location of the causative mutations in the VWF protein.1

Among type 2 variants, VWD type 2B (VWD2B) is unique because of its peculiar pathophysiology and laboratory phenotype.2 This was first shown by Ruggeri et al who identified a group of VWD patients, now classified as type VWD2B, with variable reduction of plasma VWF, but with in vitro ristocetin-induced platelet agglutination (RIPA) occurring at concentrations lower than those required for normal controls and other patients with VWD.3 Subsequently, a lack of high-molecular-weight (HMW) multimers of VWF in plasma was observed and attributed to a heightened interaction of the abnormal VWF with the physiological glycoprotein (Ib-α; GpIb-α) receptor on platelet membrane.4 Furthermore, increasing plasma concentration of this mutant protein by administering desmopressin (DDAVP) could induce a variable degree of thrombocytopenia, which was however, already present at baseline in a significant proportion of patients.5,6 VWD2B is a rare (~3% of all VWD cases), usually highly penetrant autosomally inherited bleeding disorder caused by gain-of-function mutations in A1 domain of VWF.6 Around 50% of patients with this type exhibit mild-to-moderate thrombocytopenia, which can be unraveled or further aggravated by some clinical circumstances (e.g., surgery, infection,
pregnancy), because of the increased release of the abnormal VWF by the endothelial cells. 

Genetic Background and Heterogeneity of Laboratory Phenotypes

Along with type 2A, VWD2B was the first type of VWD for which demonstration of specific causative VWF mutation has been provided. The identification of specific segments in the A1 domain responsible for the interaction with platelet GpIb-α receptor has led to investigating exon 28 of VWF gene, which codes for A1 domain. Several mutations, all clustered in exon 28 have been associated with VWD2B (–Table 2) (also see, http://www.ragtimedesign.com/vwf/mutation/), for most of them expression experiments have clearly demonstrated the causative role of the amino acid change. Most VWD2B mutations are nonsense, of which R1306W, R1308C, V1316M, and R1341Q represent approximately 80 to 90% of the observed mutations. For some of these mutations, there is a clear relationship with loss of HMW multimers and chronic thrombocytopenia while it has been shown that P1266L mutation, previously reported as type New York/Malmo VWD, is invariably not associated with loss of HMW multimers and thrombocytopenia.

How Type 2B VWF Influences Platelets

Patients with some mutations (e.g., I1309V, V1316M) are particularly prone to develop thrombocytopenia at baseline or after triggering clinical situations, while in others it does not occur at all (e.g., P1266Q/L or 3923C>T R1308L). Thrombocytopenia inversely correlates with the increase of circulating levels of conformational active form of type 2B VWF, which may also interact spontaneously with GpIb-α

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Classification of VWD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantitative deficiency of VWF</td>
<td>Qualitative deficiency of VWF (variant VWD)</td>
</tr>
<tr>
<td>Type 1: Partial quantitative deficiency of VWF</td>
<td>Type 2: Qualitative deficiency of VWF</td>
</tr>
<tr>
<td>Type 3: Virtually complete deficiency of VWF</td>
<td>Type 2A: Qualitative variants with decreased platelet-dependent function associated with the absence of high- and intermediate-molecular-weight VWF multimers</td>
</tr>
<tr>
<td>Type 2B: Qualitative variants with increased affinity for platelet GPIb</td>
<td>Type 2M: Qualitative variants with decreased platelet-dependent function not caused by the absence of high-molecular-weight VWF multimers</td>
</tr>
<tr>
<td>Type 2N: Qualitative variants with markedly decreased affinity for factor VIII</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: GpIb, glycoprotein Ib; VWD, von Willebrand disease; VWF, von Willebrand factor. Source: Modified from Sadler et al.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Mutations identified in exon 28 of VWF gene associated with type 2B VWD phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucleotide change</td>
<td>Amino acid substitution</td>
</tr>
<tr>
<td>3797C &gt; T or A</td>
<td>P1266L/Q</td>
</tr>
<tr>
<td>3802C &gt; A or G</td>
<td>H1268N/D</td>
</tr>
<tr>
<td>3910A &gt; G</td>
<td>M1304V</td>
</tr>
<tr>
<td>3912insATG</td>
<td>M1304insM</td>
</tr>
<tr>
<td>3916C &gt; T</td>
<td>R1306W</td>
</tr>
<tr>
<td>3917G &gt; A</td>
<td>R1306Q</td>
</tr>
<tr>
<td>3917G &gt; T</td>
<td>R1306L</td>
</tr>
<tr>
<td>3922C &gt; T</td>
<td>R1308C</td>
</tr>
<tr>
<td>3923G &gt; C</td>
<td>R1308P</td>
</tr>
<tr>
<td>3925A &gt; G</td>
<td>I1309V</td>
</tr>
<tr>
<td>3929C &gt; T</td>
<td>S1310F</td>
</tr>
<tr>
<td>3939G &gt; C</td>
<td>W1313C</td>
</tr>
<tr>
<td>3940C &gt; G</td>
<td>V1314L</td>
</tr>
<tr>
<td>3941T &gt; A</td>
<td>V1314D</td>
</tr>
<tr>
<td>3946G &gt; A</td>
<td>V1316M</td>
</tr>
<tr>
<td>4010C &gt; T</td>
<td>P1337L</td>
</tr>
<tr>
<td>4021C &gt; T</td>
<td>R1341W</td>
</tr>
<tr>
<td>4022G &gt; A or C or T</td>
<td>R1341Q/P/L</td>
</tr>
<tr>
<td>4115T &gt; G</td>
<td>I1372S</td>
</tr>
<tr>
<td>4378C &gt; G</td>
<td>L1460V</td>
</tr>
<tr>
<td>4382C &gt; A or T</td>
<td>A1461D/V</td>
</tr>
</tbody>
</table>

Abbreviation: VWD, von Willebrand disease.

Apart from affecting the interaction with GpIb-α, recent findings suggest that 2B VWF may also affect platelet production. In addition to platelet aggregates, in peripheral blood smears of VWD2B patients giant platelets may also be evident. Of note, recently it has been shown that the disorder previously called Montreal platelet syndrome, characterized by thrombocytopenia with large platelets and bleeding symptoms, is indeed caused by the V1316M VWF mutation. Megakaryocytes from patients with VWD2B have an altered morphology and produce abnormal and fewer platelets than normal controls, suggesting that the continuous interaction with GpIb-α of abnormal VWF during megakaryocytes maturation influences the formation of platelets in these patients. Recently, in a murine model for VWD2B, which reproduces the phenotype observed in human patients with the disorder, Casari et al found that murine VWD2B platelets, again depending on the type of mutation, have a variably shorter circulatory survival than wild-type platelets, which could contribute to the lower platelet count in VWD2B mice. This underlines the role of VWF-type 2B in inducing the formation of abnormal platelets with shortened lifespan in circulation. Importantly, further analysis revealed that VWF-type 2B is exclusively present at the surface of platelets of thrombocytopenic VWD2B mice, suggesting that VWF binding to platelets is needed to induce thrombocytopenia.
These VWF–platelet complexes are taken up efficiently by macrophages in the liver and spleen, thus accelerating their clearance. Interestingly, increase of circulating levels of conformational active form of 2B VWF also promotes VWF binding by macrophages. Macrophage depletion leads to a two- to threefold increase of platelet counts in thrombocytopenic mice with type 2B V1316M mutation, characterized by the most severe thrombocytopenia. Furthermore, it was recently found that activation of VWF via exposure to shear stress, enhances macrophage uptake, thus contributing significantly to the clearance of VWF.

Thus, thrombocytopenia in VWD2B appears to be the result of at least a combination of shortened survival of the abnormal platelets and of an accelerated clearance of the abnormal VWF/platelet complexes by macrophages in the liver and spleen. VWD2B appears to not only be a disorder of a plasma hemostatic protein, but also of platelets, suggesting that, in addition to VWF/factor VIII concentrates, transfusion of normal platelets may be justified in VWD2B patients with bleeding and worsening of their thrombocytopenia due to hemostatic stress situations.

Furthermore, recent studies from the same group demonstrated that also platelet dysfunction is present in VWD2B. A dysregulated platelet signaling upon binding to GpIb-α, which severely impairs platelet aggregation, secretion and platelet spreading was in fact demonstrated on the basis of a decreased activation of the platelet fibrinogen integrin receptor αIIbβ3 as a consequence of type 2B VWF binding to GpIb-α. This altered platelet function would of course add to increase the risk of bleeding carried by low VWF with loss of HMW multimers and thrombocytopenia.

**Proteolysis and Clearance of Type 2B Von Willebrand Factor**

Loss of HMW multimers in VWD2B is due to increased ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) proteolysis. Furthermore, low-density lipoprotein receptor-related protein 1 (LRP1) plays a major role in shear-dependent macrophage-mediated clearance of VWF, and binds VWF exclusively under conditions of elevated shear-stress forces. It has been demonstrated that the VWF A1 domain contains an interactive site for LRP1 and that the degree of this site exposure is modulated by peculiar VWD2B mutations. Recent evidence has been provided to show that some VWD2B mutations display shear-stress independent binding to LRP1. Furthermore, in a mouse model macrophage-LRP1 contributes to increased clearance of R1306Q and V1316M in vivo even without shear stress, explaining the increased clearance of these type 2B mutations.

**Laboratory Diagnosis**

A wide heterogeneity of laboratory phenotypes is evident in VWD2B, being strictly associated with the causative mutation. The hallmark unifying all the different types of mutations, however, is the evidence of an heightened response to low concentrations of ristocetin in the RIPA assay. Usually, the laboratories screen for VWD2B by using a ristocetin concentration of 0.5 mg/mL and a response is defined as the concentration of ristocetin able to induce at least 30% of the aggregation amplitude after 3 minutes from its addition to patient’s platelet rich plasma. This occurs at higher doses than 0.5 mg/mL with some mutations (e.g., P1266L) while at lower doses (even 0.3 mg/mL) with others (V1316M). Variable reduction of plasma VWF antigen (VWF:Ag) and VWF ristocetin cofactor (VWF:RCo) is observed, but also normal levels have been reported and VWF:RCo/VWF:Ag ratio may also be normal, at variance with type 2A and type 2M. Also, FVIII may be normal or only slightly reduced. There is a tendency for fluctuating levels of both VWF:RCo and VWF:RCo/VWF:Ag ratio according to the degree of ongoing type 2B VWF–platelet interaction.

Loss of HMW and sometimes intermediate-molecular-weight multimers is typically present in patients with the mutations more frequently associated with thrombocytopenia (V1316M, R1308C) while the profile is normal in patients with the previously defined New York/Malmoe subtype (P1266L). In keeping with the demonstrated increased binding to specific LPR1 receptors, VWF propeptide to VWF:Ag ratio is increased, which represents a sensitive index of increased VWF clearance.

VWD2B must be distinguished from a platelet disorder expressing similar laboratory phenotype, named platelet-type VWD (PT-VWD), in which gain-of-function mutations in platelet GpIb-α similarly cause loss of plasma HMW VWF multimers, variable thrombocytopenia, and enhanced RIPA. Several laboratory methods have been developed to discriminate between the two disorders, including cryoprecipitate challenge and simplified RIPA mixing assays, but only the identification of specific mutations in GPIBA gene will clarify the different pathophysiology. In addition, recent evidences suggest that the bleeding tendency is milder in PT-VWD patients.

VWD2B should be always considered in the presence of inherited chronic thrombocytopenia with large platelets on blood smear. This would also help to avoid misleading therapeutic approaches, including corticosteroids and splenectomy, as observed in the experience of the authors (G.C. and A.B., data not shown). Furthermore, in those patients with thrombocytopenia, family studies could help showing the high consistency of platelet count abnormality associated with the lifelong bleeding tendency.

**Clinical Management of VWD2B: Bleeding Phenotype and Therapy**

As for the other patients with significantly low VWF, bleeding tendency in VWD2B is mainly represented by mucocutaneous bleeding. The severity and frequency of bleeding symptoms and requirement of substitutive treatment is somewhat similar to what is observed in type 2A and more severe that typical type 2M and type 1. From a clinical point of view, the risk of bleeding is approximately fivefold higher in VWD2B patients with associated thrombocytopenia below $140 \times 10^9$ platelets/µL compared with those with normal platelet counts. However, wide variation again exists...
alloantibodies to VWF are rare and reported to occur mainly in type 3 patients in whom no VWF is synthesized in association with homozygous null mutations, including gene deletions. However, the occurrence of alloantibodies to VWF in a patient with VWD2B (R1308C mutation) after substitutive treatment has been recently reported. Interestingly, the antibody specificity seems to be restricted toward the active platelet-binding conformation of the A1 domain of VWF. Following this report, it appears that closely monitored measurement of FVIII/VWF activities after substitutive treatment is advised, especially after intensive treatment in previously minimally treated patients.

**Conclusions**

VWD2B represents a rare, but fascinating bleeding disorder, which displays a wide heterogeneity of laboratory and clinical phenotypes. The interaction of type 2B VWF and platelet production and function is worthy of further studies to elucidate this complex interaction. Identifying the responsible VWD2B mutation appears relevant not only to distinguish it from the PT-VWD, but also to predict the severity of bleeding tendency and type of treatment.

**References**

4. Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric
18 Castaman G. 2B or not 2B: when VWF is not a good platelet friend. Blood 2013;122(16):2772–2773